Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EP 1090

Next Previous
Drug Profile

EP 1090

Alternative Names: EP-1090; EP-HIV-1090; HIV DNA vaccine - VaxOnco; Pharmexa-Epimmune HIV-1 CTL epitope-based DNA vaccine

Latest Information Update: 24 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmexa-Epimmune
  • Developer VaxOnco
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 28 May 2009 Pharmexa Epimmune has been acquired and merged into VaxOnco
  • 07 Feb 2006 Phase-I clinical trials in HIV-1 infections in Peru (IM)
  • 15 Sep 2005 Data from a media release have been added to the adverse events and Viral infections therapeutic trials sections

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top